Merck Serono to fund own R&D group at in-demand Ablynx
This article was originally published in Scrip
Belgium firm Ablynx, which is having major news flow this week following a major deal with AbbVie, has now expanded its relationship with Merck Serono through a multi-year research alliance that the partners say could lead to at least four co-discovery and co-development collaborations.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.